Brokers Set Expectations for Alector, Inc.’s Q1 2025 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – Equities researchers at William Blair issued their Q1 2025 earnings per share (EPS) estimates for Alector in a research note issued to investors on Thursday, August 8th. William Blair analyst M. Minter forecasts that the company will earn ($0.47) per share for the quarter. The consensus estimate for Alector’s current full-year earnings is ($1.93) per share. William Blair also issued estimates for Alector’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.44) EPS, FY2027 earnings at $2.06 EPS and FY2028 earnings at $25.50 EPS.

ALEC has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Alector in a research report on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a report on Monday, July 29th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, Alector has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

Alector Trading Up 3.9 %

ALEC stock opened at $5.10 on Friday. The stock has a market cap of $491.56 million, a P/E ratio of -3.70 and a beta of 0.72. Alector has a twelve month low of $3.66 and a twelve month high of $8.90. The company’s 50 day moving average is $5.08 and its two-hundred day moving average is $5.61.

Alector (NASDAQ:ALEC) last issued its earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $15.08 million for the quarter, compared to analyst estimates of $16.04 million. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. During the same quarter last year, the company earned $0.02 EPS.

Institutional Investors Weigh In On Alector

Several large investors have recently modified their holdings of the stock. Gladius Capital Management LP purchased a new position in Alector in the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Alector in the first quarter valued at about $40,000. Lazard Asset Management LLC purchased a new stake in shares of Alector in the first quarter valued at about $59,000. E Fund Management Co. Ltd. acquired a new position in shares of Alector during the fourth quarter worth about $81,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Alector by 89.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 18,403 shares of the company’s stock worth $111,000 after purchasing an additional 8,670 shares in the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Insider Transactions at Alector

In related news, CEO Arnon Rosenthal sold 25,135 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now owns 1,975,245 shares in the company, valued at approximately $9,481,176. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Alector news, CFO Marc Grasso sold 6,920 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $33,216.00. Following the completion of the sale, the chief financial officer now directly owns 138,037 shares of the company’s stock, valued at approximately $662,577.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the transaction, the chief executive officer now owns 1,975,245 shares in the company, valued at $9,481,176. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,095 shares of company stock worth $192,456. Insiders own 9.10% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.